Highlights 2023 Elevate-Derm Poster Session
- In:
Clinical Practice
- Patients using IDP-126 triple ingredient acne topical had a >50% reduction in acne at 12 weeks than all dual ingredient topicals.
- Patients with moderate-severe atopic dermatitis present with heterogeneous disease course subtypes which can guide therapy choice and implementation.
- The majority of psoriasis patients who were treated for 52 weeks with deucravacitinib maintained or lowered cholesterol and triglyceride levels.